OncoMatch/Clinical Trials/NCT07123454
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Is NCT07123454 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies AZD4512 for b-cell non-hodgkin lymphoma.
Treatment: AZD4512 — This is a Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy — relapsed/refractory B-cell Non-Hodgkin Lymphoma
relapsed or refractory disease after at least two prior lines of systemic therapy and lack additional standard options with established benefit
Must have received: anti-CD20 therapy — LBCL
LBCL patients must have progressed after both anti-CD20 and at least one systemic chemotherapy regimen
Must have received: systemic chemotherapy — LBCL
LBCL patients must have progressed after both anti-CD20 and at least one systemic chemotherapy regimen
Must have received: anti-CD20 therapy — Mantle cell lymphoma
Mantle cell lymphoma (MCL) patients must have had anti-CD20 and Bruton's Tyrosine Kinase (BTK) inhibitor
Must have received: BTK inhibitor — Mantle cell lymphoma
Mantle cell lymphoma (MCL) patients must have had anti-CD20 and Bruton's Tyrosine Kinase (BTK) inhibitor
Lab requirements
Blood counts
adequate bone marrow function as specified by blood counts
Kidney function
adequate renal parameters as specified by protocol
Liver function
adequate hepatic parameters as specified by protocol
Cardiac function
adequate cardiac ejection fraction as specified by protocol
adequate organ and bone marrow function (as specified by blood counts, cardiac ejection fraction, renal and hepatic parameters, and coagulation indices)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Myrtle Beach, South Carolina
- Research Site · Franklin, Tennessee
- Research Site · Irvine, California
- Research Site · Jacksonville, Florida
- Research Site · Rochester, Minnesota
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07123454 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy and anti-CD20 therapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages